CDKN2B-AS1 and coronary artery disorder: This latter experimental evidence has recently been mirrored by clinical data revealing that miR-181b acts jointly with the lncRNA ANRIL to mediate the NF-κB signaling, and was therefore proposed as a promising risk biomarker to identify high-risk patients with coronary artery disease (CAD) [105].